Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Novartis : Gets Funds From Bill & Melinda Gates Foundation to Treat Cryptosporidiosis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/14/2018 | 01:50am EST
   By Marc Bisbal Arias 
 

Novartis AG (NOVN.EB) said Wednesday that it has signed an alliance with the Bill & Melinda Gates Foundation for further development of a drug that treats the diarrheal disease cryptosporidiosis.

The Swiss company said that the Gates Foundation will provide $6.5 million to support the development of Novartis's drug candidate KDU731.

"Cryptosporidiosis is the second leading cause of infectious diarrhea in children under two years of age," Novartis said. Diarrheal diseases cause around 525,000 deaths a year.

Write to Marc Bisbal Arias at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
05:56aUnited Therapeutics slips on further delays for RemoSynch
AQ
05:55aNOVARTIS : New fluorination method expands medicinal chemistry toolbox
AQ
01:16aNOVARTIS : Treatment with Novartis' Ultibro® Breezhaler® improved cardiac functi..
GL
02/21NOVARTIS : Builds Up R&D -- WSJ
DJ
02/20NOVARTIS : new Cosentyx data confirms robust efficacy and quality of life improv..
AQ
02/19NOVARTIS : Correction to Novartis CEO story
DJ
02/19Oncology Biosimilar Market to Grow at a High CAGR by 2025 - Top Players Inclu..
AQ
02/19Oncology Biosimilar Market to Grow at a High CAGR by 2025 – Top Players..
AQ
02/18NOVARTIS : CEO Steers Drug Maker Back to R&D
DJ
02/17NOVARTIS : New Data Show Cosentyx Improved Quality of Life Over 5 Years in Two T..
AQ
More news
News from SeekingAlpha
02/21Tracking Tweedy Browne Portfolio - Q4 2017 Update 
02/21UNDERVALUED AND ATTRACTIVE : Pick Up Novartis In 2018 
02/20BIOTECHS : Still Well Placed For More Gains 
02/20Conatus Pharmaceuticals Has A Golden Opportunity With Upcoming Phase 2 Liver .. 
02/19Warren Buffett's Berkshire Claims $358 Million Investment In Teva, But That D.. 
Financials ($)
Sales 2018 51 967 M
EBIT 2018 13 392 M
Net income 2018 8 906 M
Debt 2018 18 146 M
Yield 2018 3,54%
P/E ratio 2018 21,07
P/E ratio 2019 19,24
EV / Sales 2018 4,66x
EV / Sales 2019 4,46x
Capitalization 224 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 93,2 $
Spread / Average Target 9,1%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
André Wyss President-Novartis Operations
Harry Kirsch Chief Financial Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-2.67%224 221
JOHNSON & JOHNSON-7.19%357 710
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 826
MERCK AND COMPANY-0.50%153 359
AMGEN3.23%132 827